Saizen

Phase 3Small molecule

Merck & Co.

Saizen is one of 106 small molecule programs targeting Small for gestational age. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small for Gestational AgeActive, not recruiting

Short StatureActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

FibromyalgiaActive, not recruiting

GrowthActive, not recruiting

Small for Gestational AgePhase 3

Active, not recruiting

Short StaturePhase 3

Active, not recruiting

Growth Hormone DeficiencyPhase 3

Active, not recruiting

FibromyalgiaPhase 3

Active, not recruiting

GrowthPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Saizen

Merck & Co.

Phase 3

2 2

Lovenox

Sanofi

Preclinical

2 3

Zolymbus

AbbVie

Preclinical

1 4

Aricept

Eisai

Preclinical

1 5

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 6

Lenvima

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

EGRIFTA WR

2 10

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth Hormone Deficiency3 trials

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

Terminated· EMD Serono logo

EMD Serono·Phase 3·NCT01237340·59 enrolled

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01806298·78 enrolled

Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00256126·318 enrolled

Growth2 trials

Growth Hormone in Poor Responders to IVF Trial

Terminated·PPacific Centre for Reproductive Medicine·Phase 2/3·NCT01616225·60 enrolled

Saizen in Intra-uterine Growth Retardation

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01400698·91 enrolled

Fibromyalgia1 trial

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00933686·113 enrolled

Short stature1 trial

A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01746862·90 enrolled

Small for gestational age1 trial

Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00249821·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Saizen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Saizen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Saizen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Saizen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth Hormone Deficiency3 trials

Growth2 trials

Fibromyalgia1 trial

Short stature1 trial

Small for gestational age1 trial

References

Drug Info

Quick Facts

Related News